Tommy Andersson, CSO, WntResearch has for personal and financial reasons sold a small amount of his shares in WntResearch. After this, Tommy Andersson still has a significant number of shares in WntResearch. It should be stressed that Tommy Andersson does not have any insider information about the ongoing clinical phase I study or on other activities in WntResearch which would influence the share price. The Company’s clinical phase I study is running according to the plans and no dose limiting toxicity has been observed. For additional information please contact: Nils Brünner, VD E-post: nbr@wntresearch.com/nbr@sund.ku.dk Telefon: + 45 2614 4708 Om WntResearch WntResearch AB is a public Company on the AktieTorget in Sweden. WntResearch develops anti-cancer drugs to be used to combat metastatic spread of cancer cells. WntResearch has one drug candidate in clinical phase I study – Foxy-5- and one drug candidate in preclinical development – Box-5. The Company is currently mainly focusing on the development of Foxy-5.